Zilovertamab/Ibrutinib Elicits Durable Responses With Favorable Tolerability in MCL and CLL
December 11th 2022The combination of zilovertamab and ibrutinib resulted in promising clinical response and progression-free survival rates and showcased a tolerable toxicity profile in patients with mantle cell lymphoma and chronic lymphocytic leukemia.
Rapcabtagene Autoleucel Induces Deep, Durable Responses in Relapsed/Refractory DLBCL
December 11th 2022The CD19-targeted CAR T-cell therapy rapcabtagene autoleucel was found to be well tolerated and to yield durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma who had undergone 2 or more prior lines of therapy.
Ziftomenib Showcases Clinical Activity, Favorable Tolerability in Relapsed/Refractory AML
December 11th 2022Ziftomenib monotherapy had a manageable toxicity profile and provided pronounced antileukemic activity when given at a 600-mg dose in heavily pretreated patients with relapsed or refractory acute myeloid leukemia.
Pirtobrutinib Shows High Response Rates in Heavily Pretreated Waldenström Macroglobulinemia
December 11th 2022The non-covalent BTK inhibitor pirtobrutinib showed high levels of response in heavily pretreated patients with Waldenström macroglobulinemia, regardless of prior treatment with a covalent BTK inhibitor.
Teclistamab Triplet Shows Encouraging Responses and Safety in Relapsed/Refractory Multiple Myeloma
December 10th 2022Administration of teclistamab in combination with daratumumab and lenalidomide demonstrated promising overall response rates and tolerability in patients with relapsed/refractory multiple myeloma who had prior lenalidomide exposure, according to initial data from the phase 1b MajesTEC-2 trial.
Lintuzumab-Ac225 With Intensive Chemo Has Encouraging Efficacy Signal in High-risk AML
December 10th 2022Sequential administration of lintuzumab-Ac225 after salvage chemotherapy proved to be safe and feasible, and to result in high response and minimal residual disease negativity rates in high-risk patients with relapsed/refractory acute myeloid leukemia.
ARV-471 Monotherapy Demonstrates Clinical Benefit in ER+/HER2- Advanced Breast Cancer
December 8th 2022ARV-471 monotherapy elicited a significant clinical benefit rate in patients with estrogen receptor–positive/HER2-negative locally advanced or metastatic breast cancer who had undergone prior hormonal therapy and chemotherapy, including those with ESR1 mutations.
FDA Grants Fast Track Designation to Pelareorep for Advanced/Metastatic Pancreatic Cancer
December 1st 2022The FDA has granted a fast track designation to pelareorep for use in combination with atezolizumab, gemcitabine, and nab-paclitaxel for the treatment of patients with advanced or metastatic pancreatic cancer.